NeOnc CEO Amir Heshmatpour’s 2026 Open-Market Share Purchases Exceed $1.5 Million
Key Highlights
- ➤Heshmatpour purchased 371,000 shares for more than $1.5 million in 2026
- ➤Heshmatpour bought 291,000 shares for more than $1 million since August 12
- ➤FDA Type B End-of-Phase meeting scheduled for early January 2027
- ➤Meeting will address potential accelerated approval and NEO100 Phase 3 design
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings
“I’ve continued to buy NeOnc shares with my own funds because I believe in the work our team is doing for patients with brain cancer.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings
“That conviction has only grown after spending time with children receiving investigational NEO100 through our compassionate care program at Burjeel Medical City in Abu Dhabi.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings
“What I’ve witnessed firsthand there has stayed with me.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings
“As I’ve said before, I believe God’s hand is in this work.”
CALABASAS, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) today announced that Amir F. Heshmatpour, its Executive Chairman, President and Chief Executive Officer, purchased 30,000 shares of NeOnc common stock on the open market on November 13, 2026. The transaction brings his 2026 open-market purchases to 371,000 shares for more than $1.5 million, including 180,000 shares in November. Mr. Heshmatpour used personal funds, and NeOnc issued no shares in connection with the purchases.
Since NeOnc reported topline Phase 2a results for intranasal NEO100 on August 12, 2026, Mr. Heshmatpour has purchased 291,000 shares for more than $1 million.
Get started
Create a free account to read the full story.
